$13.02
+0.02
(+0.15%)▲
Insights on Orthofix Medical Inc
Revenue is up for the last 2 quarters, 184.00M → 200.41M (in $), with an average increase of 8.2% per quarter
Netprofit is up for the last 4 quarters, -60.93M → -22.17M (in $), with an average increase of 40.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 58.2%
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 136.7%
0.38%
Downside
Day's Volatility :2.63%
Upside
2.25%
26.5%
Downside
52 Weeks Volatility :55.69%
Upside
39.72%
Period | Orthofix Medical Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.89% | -0.7% | 0.0% |
6 Months | 6.56% | 6.6% | 0.0% |
1 Year | -26.51% | 3.7% | -1.5% |
3 Years | -70.3% | 14.0% | -21.8% |
Market Capitalization | 493.0M |
Book Value | $16.11 |
Earnings Per Share (EPS) | -4.12 |
PEG Ratio | 0.33 |
Wall Street Target Price | 18.47 |
Profit Margin | -20.28% |
Operating Margin TTM | -1.98% |
Return On Assets TTM | -6.3% |
Return On Equity TTM | -32.36% |
Revenue TTM | 746.6M |
Revenue Per Share TTM | 20.33 |
Quarterly Revenue Growth YOY | 64.0% |
Gross Profit TTM | 337.2M |
EBITDA | -9.2M |
Diluted Eps TTM | -4.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.44 |
EPS Estimate Next Year | 0.24 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.13 |
What analysts predicted
Upside of 41.86%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 453.0M | ↑ 4.43% |
Net Income | 13.8M | ↑ 121.93% |
Net Profit Margin | 3.05% | ↑ 1.62% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 460.0M | ↑ 1.53% |
Net Income | -28.5M | ↓ 306.08% |
Net Profit Margin | -6.19% | ↓ 9.24% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 406.6M | ↓ 11.61% |
Net Income | 2.5M | ↓ 108.84% |
Net Profit Margin | 0.62% | ↑ 6.81% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 464.5M | ↑ 14.25% |
Net Income | -38.4M | ↓ 1624.79% |
Net Profit Margin | -8.26% | ↓ 8.88% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 460.7M | ↓ 0.81% |
Net Income | -19.7M | ↓ 48.54% |
Net Profit Margin | -4.29% | ↑ 3.97% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 746.6M | ↑ 62.06% |
Net Income | -151.4M | ↑ 666.6% |
Net Profit Margin | -20.28% | ↓ 15.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 114.0M | ↓ 3.45% |
Net Income | -10.7M | ↓ 530.53% |
Net Profit Margin | -9.4% | ↓ 11.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 122.2M | ↑ 7.22% |
Net Income | -7.1M | ↓ 34.1% |
Net Profit Margin | -5.78% | ↑ 3.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 175.2M | ↑ 43.34% |
Net Income | -60.9M | ↑ 762.9% |
Net Profit Margin | -34.78% | ↓ 29.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 187.0M | ↑ 6.74% |
Net Income | -39.4M | ↓ 35.3% |
Net Profit Margin | -21.08% | ↑ 13.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 184.0M | ↓ 1.61% |
Net Income | -28.9M | ↓ 26.81% |
Net Profit Margin | -15.68% | ↑ 5.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 200.4M | ↑ 8.92% |
Net Income | -22.2M | ↓ 23.16% |
Net Profit Margin | -11.06% | ↑ 4.62% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 466.6M | ↑ 15.12% |
Total Liabilities | 131.2M | ↑ 20.69% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 495.6M | ↑ 6.21% |
Total Liabilities | 168.0M | ↑ 28.0% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 525.9M | ↑ 6.1% |
Total Liabilities | 169.0M | ↑ 0.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 476.6M | ↓ 9.36% |
Total Liabilities | 139.7M | ↓ 17.34% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 458.6M | ↓ 3.78% |
Total Liabilities | 121.8M | ↓ 12.83% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 925.3M | ↑ 101.76% |
Total Liabilities | 326.6M | ↑ 168.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 449.7M | ↓ 2.6% |
Total Liabilities | 116.1M | ↓ 3.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 458.6M | ↑ 1.99% |
Total Liabilities | 121.8M | ↑ 4.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 917.1M | ↑ 99.97% |
Total Liabilities | 253.0M | ↑ 107.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 901.3M | ↓ 1.73% |
Total Liabilities | 261.3M | ↑ 3.29% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 905.7M | ↑ 0.48% |
Total Liabilities | 290.2M | ↑ 11.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 925.3M | ↑ 2.17% |
Total Liabilities | 326.6M | ↑ 12.55% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 49.9M | ↓ 6.42% |
Investing Cash Flow | -61.0M | ↑ 270.27% |
Financing Cash Flow | 3.0M | ↓ 15.4% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 32.0M | ↓ 35.83% |
Investing Cash Flow | -22.9M | ↓ 62.42% |
Financing Cash Flow | -10.7M | ↓ 457.1% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 74.3M | ↑ 131.86% |
Investing Cash Flow | -52.3M | ↑ 128.29% |
Financing Cash Flow | 3.2M | ↓ 130.36% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.5M | ↓ 75.13% |
Investing Cash Flow | -23.0M | ↓ 56.03% |
Financing Cash Flow | -3.6M | ↓ 211.59% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.5M | ↓ 162.45% |
Investing Cash Flow | -24.5M | ↑ 6.61% |
Financing Cash Flow | -78.0K | ↓ 97.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.3M | ↓ 74.27% |
Investing Cash Flow | -5.5M | ↓ 26.97% |
Financing Cash Flow | -252.0K | ↓ 127.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.3M | ↓ 285.76% |
Investing Cash Flow | -5.9M | ↑ 7.8% |
Financing Cash Flow | 1.5M | ↓ 694.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.0M | ↓ 1548.89% |
Investing Cash Flow | 17.1M | ↓ 389.56% |
Financing Cash Flow | 16.0M | ↑ 966.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↓ 83.79% |
Investing Cash Flow | -12.8M | ↓ 175.04% |
Financing Cash Flow | 5.8M | ↓ 63.66% |
Sell
Neutral
Buy
Orthofix Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Orthofix Medical Inc | -2.33% | 6.56% | -26.51% | -70.3% | -75.26% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Orthofix Medical Inc | NA | NA | 0.33 | -0.44 | -0.32 | -0.06 | NA | 16.11 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Orthofix Medical Inc | Buy | $493.0M | -75.26% | NA | -20.28% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
Rubric Capital Management LP
Armistice Capital, LLC
BlackRock Inc
Engine Capital Management LP
Morgan Stanley - Brokerage Accounts
Vanguard Group Inc
Orthofix Medical Inc’s price-to-earnings ratio stands at None
Read Moreorthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing
Organization | Orthofix Medical Inc |
Employees | 1634 |
CEO | Ms. Kimberley A. Elting |
Industry | Health Technology |